Neurocrine Biosciences
NBIX
#1655
Rank
HK$103.82 B
Marketcap
HK$1,035
Share price
1.23%
Change (1 day)
12.04%
Change (1 year)
Neurocrine Biosciences is an American biopharmaceutical company that develops treatments for neurological and endocrine-related diseases and disorders.

Revenue for Neurocrine Biosciences (NBIX)

Revenue in 2024: HK$18.28 Billion

According to Neurocrine Biosciences 's latest financial reports the company's current revenue (TTM ) is HK$20.98 Billion. In 2024 the company made a revenue of HK$18.28 Billion an increase over the revenue in the year 2023 that were of HK$14.73 Billion. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.

Revenue history for Neurocrine Biosciences from 1996 to 2024

Annual revenue

Year Revenue Change
2024HK$18.28 B24.07%
2023HK$14.73 B26.71%
2022HK$11.63 B31.6%
2021HK$8.83 B9.01%
2020HK$8.10 B32.11%
2019HK$6.13 B73.68%
2018HK$3.53 B179.83%
2017HK$1.26 B985.62%
2016HK$0.11 B-24.09%
2015HK$0.15 B
2014N/A-100%
2013HK$22.63 M-94.5%
2012HK$0.41 B-31.49%
2011HK$0.60 B130.62%
2010HK$0.26 B1038.64%
2009HK$22.89 M-25.46%
2008HK$30.71 M221.86%
2007HK$9.54 M-96.87%
2006HK$0.30 B-68.23%
2005HK$0.96 B45.12%
2004HK$0.66 B-38.6%
2003HK$1.07 B666.05%
2002HK$0.14 B-56.24%
2001HK$0.32 B182.65%
2000HK$0.11 B-12.88%
1999HK$0.13 B5.35%
1998HK$0.12 B-38.71%
1997HK$0.20 B36.2%
1996HK$0.14 B

Revenue for similar companies or competitors

Company Revenue Revenue differencediff. Country
Pfizer
PFE
HK$491.14 B 2,240.40%๐Ÿ‡บ๐Ÿ‡ธ USA
AbbVie
ABBV
HK$466.56 B 2,123.28%๐Ÿ‡บ๐Ÿ‡ธ USA
Eli Lilly
LLY
HK$464.81 B 2,114.93%๐Ÿ‡บ๐Ÿ‡ธ USA
Repligen
RGEN
HK$5.53 B-73.61%๐Ÿ‡บ๐Ÿ‡ธ USA
Athersys
ATHX
HK$0.62 M-100.00%๐Ÿ‡บ๐Ÿ‡ธ USA
ANI Pharmaceuticals
ANIP
HK$6.46 B-69.18%๐Ÿ‡บ๐Ÿ‡ธ USA
Palatin Technologies
PTN
HK$69.2 M-99.67%๐Ÿ‡บ๐Ÿ‡ธ USA
Royalty Pharma
RPRX
HK$18.38 B-12.41%๐Ÿ‡ฌ๐Ÿ‡ง UK